The House Judiciary Committee is marking up several bills dealing with the pricing of prescription drugs.
April 30, 2019

Among several bills, the committee will be marking up this:

The bipartisan bill, the Prescription Pricing for the People Act of 2019, helps shed light on the pharmacy benefit manager (PBM) industry by examining the effects of consolidation on pricing and other potentially-abusive behavior. Specifically, the bill requires the Federal Trade Commission (FTC) to study the role and recent merger activity of PBMs as well as possible anticompetitive behavior. The bill requires the FTC to provide policy recommendations to Congress to improve competition and protect consumers.

Can you help us out?

For 17 years we have been exposing Washington lies and untangling media deceit, but now Facebook is drowning us in an ocean of right wing lies. Please give a one-time or recurring donation, or buy a year's subscription for an ad-free experience. Thank you.


We are currently migrating to Disqus

On May 14, 2022, we started migrating our comments from Insticator back to Disqus. During this transition period, some posts will have Insticator and some Disqus. For more information on the transition, as well as information regarding old C&L accounts, please see this post.

We welcome relevant, respectful comments. Any comments that are sexist or in any other way deemed hateful by our staff will be deleted and constitute grounds for a ban from posting on the site. Please refer to our Terms of Service for information on our posting policy.